Another hot stock is Sirtris Pharmaceuticals. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. The drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activating an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins.
All in all Sirtris (NASDAQ:SIRT) is a promising investment in two ways: first its activities are in a field that affects everyone of us sooner or later. Secondly it has just a market capitalization of 340 million dollars – but its competitors are Pfizer (market cap: 152b $), Johnson & Johnson (180 b) and Eli Lilly (58 b). You get the point. One buyout offer and the stock shoots into the sky.
[...] Pharmaceuticals (NASDAQ:SIRT) When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Too bad, since exactly happened [...]